Drugs / Febuxostat XR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02128490 | May 2014 → Sep 2015 | gout | Takeda | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02139046 | Apr 2014 → Nov 2015 | gout | Takeda | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Febuxostat XR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02128490 ↗ |
| Route | Oral | “Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily” NCT02128490 ↗ |